Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04671667
Title Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

laryngeal squamous cell carcinoma

hypopharynx cancer

oral squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

Cisplatin

Pembrolizumab

Carboplatin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST